Purchase this article with an account.
X. Sun, W. Wang, W. Wang, J. Qian; Intravitreal Bevacizumab (Avastin) Combined with Agron Llaser for Treatment of Macular Edema Secondary to Retinal Vein Occlusion. Invest. Ophthalmol. Vis. Sci. 2009;50(13):5401.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
to observe the efficacy of intravitreal bevacizumab (Avastin) combined with Agron laser for treatment of macular edema secondary to retinal vein occlusion (RVO)
Retrospective review of 22 eyes of 22 patients who underwent RVO were treated with at least one intravitreal injection (2.5 mg/0.1ml) of bevacizumab combined with Argon laser photocoagulation. Patients were followed for at lest 3 month (median 6 months, range 3-13 months). Best corrected visual acuity (BCVA) ,intraocular pressure measurements (IOP), fundus photography, Fuorescein/ indocyanine green angiography (FFA/ICGA) findings , optical coherence tomography (OCT) central foveal thickness (CFT),and microperimetry (MP-1) mean sensitivity (MS) were assessed.
There were 22 consecutive patients who received intravitreal bevacizumab injections of a mean number of retreatments was 3.4. Visual acuity improved or was maintained in the majority of patients, with the mean change between baseline and the last visit being an improvement of 1.24 lines (p =0.39). Seventeen (77%) of the 22 eyes showed improved or maintained visual acuity after 3-months of follow-up. At 1 month, there was an average gain of 1.3 lines of BCVA and at last follow-up, 3.2 lines of BCVA (P = 0.05). The mean CMT +/- SD decreased from 431 +/- 191 microm at baseline to 313 +/- 167 microm at 1 month, 265 +/- 89 microm at last follow-ups. 4 (18%) of the 22 eyes continued to show sustained macular edema by the last follow-up and the side effects were not observed
Intravitreal bevacizumab injections resulted visiual and anatomic improvements in eyes with macular edema attributable to RVO. Combined with Argon laser photocoagulation could reduce the rate of recurrence of macular edema as well. However, multiple injections are needed for continued control of macular edema and preservation of visual acuity in the long term.
This PDF is available to Subscribers Only